Announced Wed, 25 Mar · 17:51 IST

Allotment of 1,06,668 Equity Shares to Promoter upon conversion of Warrants into Equity Shares

Warrants ConvertedQip At PremiumFund Raising View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.9%1-day move
₹1719.00
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.9+0.6+0.7-0.5+0.1+6.5+22.6+19.4+35.8+59.0
Up moveDown movePending
AI summary

Fredun Pharmaceuticals has allotted 1,06,668 equity shares to its promoter, Mr. Fredun Nariman Medhora, after he converted an equivalent number of warrants into shares. The warrants were originally issued on a preferential basis on December 29, 2025, at ₹1,250 per warrant. The promoter paid the remaining 75% balance consideration of ₹937.50 per warrant, totaling about ₹10 crore. Of the 1,60,000 warrants originally allotted, 53,332 are still outstanding and pending conversion. The new shares will rank equally with existing equity shares.

Likely market impact

This is a promoter-led capital infusion, which signals confidence from the promoter in the company's future. However, it also results in equity dilution for existing shareholders. The premium pricing (₹1,250 vs face value of ₹10) means the promoter is paying well above par, which is generally a positive signal.